The European Medicines Agency has warned that it may lose 30% of its staff in its upcoming move to Amsterdam, as a result of the UK leaving the EU. This revised figure is up from its previous estimate of 19% of the staff currently based in its London office.
The EMA’s Executive Director Guido Rasi also warned “in the short- to mid-term EMA will have to reprioritise its resources to fully maintain its core activities”, and it is expected that the EMA will reduce the rate at which it issues non-essential guideline revisions, and reduce stakeholder engagement, in order to compensate.
Various other factors further complicate the move, such as the need for temporary premises until the agency’s new headquarters is complete, and that employment rules in the Netherlands prevent the agency retaining 135 short-term contract staff currently working for it in the UK.
The full press release is available here.